Cargando…

Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer

Breast cancer (BC) is a highly prevalent disease, accounting for the second highest number of cancer-related mortalities worldwide. The anthracycline doxorubicin (DOX), isolated from Streptomyces peucetius var. caesius, is a potent chemotherapeutic drug that is successfully used to treat various for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franco, Yesenia L, Vaidya, Tanaya R, Ait-Oudhia, Sihem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138971/ https://www.ncbi.nlm.nih.gov/pubmed/30237735 http://dx.doi.org/10.2147/BCTT.S170239

Ejemplares similares

In vitro to clinical translation of combinatorial effects of doxorubicin and dexrazoxane in breast cancer: a mechanism-based pharmacokinetic/pharmacodynamic modeling approach
por: Mody, Hardik, et al.
Publicado: (2023)

In vitro to clinical translational pharmacokinetic/pharmacodynamic modeling of doxorubicin (DOX) and dexrazoxane (DEX) interactions: Safety assessment and optimization
por: Mody, Hardik, et al.
Publicado: (2023)

Pharmacodynamic Modeling to Evaluate the Impact of Cimetidine, an OCT2 Inhibitor, on the Anticancer Effects of Cisplatin
por: Mody, Hardik, et al.
Publicado: (2022)

Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer
por: Ande, Anusha, et al.
Publicado: (2018)

In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach
por: Fleisher, Brett, et al.
Publicado: (2021)

Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
por: Ait-Oudhia, Sihem, et al.
Publicado: (2014)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher, Brett, et al.
Publicado: (2016)

A retrospective examination of the US Food and Drug Administration’s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring
por: Fleisher, Brett, et al.
Publicado: (2017)

Leveraging the Cardio-Protective and Anticancer Properties of Resveratrol in Cardio-Oncology
por: Abdelgawad, Ibrahim Y., et al.
Publicado: (2019)

Co-delivery of doxorubicin and itraconazole by Pluronic® P123 coated liposomes to enhance the anticancer effect in breast cancers
por: Lin, Yi, et al.
Publicado: (2018)

Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
por: Lao, Juan, et al.
Publicado: (2013)

Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy
por: Robainas, Marianela, et al.
Publicado: (2017)

Mechanisms, monitoring, and management of tyrosine kinase inhibitors–associated cardiovascular toxicities
por: Chaar, Maher, et al.
Publicado: (2018)

Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells
por: Miao, Xin, et al.
Publicado: (2016)

Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study
por: Davidson, Neville, et al.
Publicado: (2014)

Chloroquine sensitizes MDA-MB-231 cells to osimertinib through autophagy–apoptosis crosstalk pathway
por: Fleisher, Brett, et al.
Publicado: (2019)

Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches
por: Kamta, Jeff, et al.
Publicado: (2017)

Anticancer Effect of Metformin in Herceptin-Conjugated Liposome for Breast Cancer
por: Lee, Ji-Yeon, et al.
Publicado: (2019)

Anticancer Effect of STING Agonist-Encapsulated Liposomes on Breast Cancer
por: Zhang, Jibing, et al.
Publicado: (2023)

Preparation, characterization, and Co-delivery of cisplatin and doxorubicin-loaded liposomes to enhance anticancer Activities
por: Bahrami Parsa, Mahdi, et al.
Publicado: (2023)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
por: Anders, Carey K., et al.
Publicado: (2013)

Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer
por: Alhaja, Maher, et al.
Publicado: (2023)

Documentation of Complete Response in Metastatic Breast Cancer to Liver and Bone Achieved with Trastuzumab and Pegylated Liposomal Doxorubicin
por: Kobrinsky, Boris, et al.
Publicado: (2008)

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
por: Pisano, Carmela, et al.
Publicado: (2013)

Reversal of Multidrug Resistance by Apolipoprotein A1-Modified Doxorubicin Liposome for Breast Cancer Treatment
por: An, Duopeng, et al.
Publicado: (2021)

Preparation of a PEGylated liposome that co-encapsulates l-arginine and doxorubicin to achieve a synergistic anticancer effect
por: Feng, Haitao, et al.
Publicado: (2021)

The Use of the QbD Approach to Optimize the Co-Loading of Simvastatin and Doxorubicin in Liposomes for a Synergistic Anticancer Effect
por: Barbalata, Cristina-Ioana, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
por: Huober, Jens, et al.
Publicado: (2010)

Gemcitabine and doxorubicin in immunostimulatory monophosphoryl lipid A liposomes for treating breast cancer
por: Wu, Debra, et al.
Publicado: (2020)

Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
por: Albini, Adriana, et al.
Publicado: (2010)

Mild Hyperthermia Responsive Liposomes for Enhanced In Vitro and In Vivo Anticancer Efficacy of Doxorubicin against Hepatocellular Carcinoma
por: Rahim, Muhammad Abdur, et al.
Publicado: (2021)

Dual-Functional Peptide Driven Liposome Codelivery System for Efficient Treatment of Doxorubicin-Resistant Breast Cancer
por: Ahmed, Kamel S, et al.
Publicado: (2021)

Short and Long-Term Effects of the Exposure of Breast Cancer Cell Lines to Different Ratios of Free or Co-Encapsulated Liposomal Paclitaxel and Doxorubicin
por: Franco, Marina Santiago, et al.
Publicado: (2019)

Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome
por: Tilemann, Lisa M., et al.
Publicado: (2018)

Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model
por: Islam, Md. Rakibul, et al.
Publicado: (2022)

A Case of Metaplastic Breast Cancer with Prolonged Response to Single Agent Liposomal Doxorubicin
por: Hamad, Lamya, et al.
Publicado: (2016)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
por: Yuan, Zhen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r637l5s74jluiult6jisooks81